Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370819 | 0.78 | SLC6A4 (0.41) | TACR1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL14027319 | 0.78 | SLC6A4 (0.41) | TACR1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5557603 | 0.78 | SLC6A2 (0.45) | TACR1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL5557599 | 0.78 | SLC6A2 (0.45) | TACR1SLC6A2SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4909632 | 0.78 | SLC6A4 (0.40) | TACR1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5768017 | 0.78 | TACR1 (0.47) | TACR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4361732 | 0.77 | TACR1 (0.46) | TACR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL14027321 | 0.77 | TACR1 (0.46) | TACR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL14181787 | 0.77 | TACR1 (0.46) | TACR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4160343 | 0.77 | TACR1 (0.42) | TACR1KDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | TACR1 180/4885MAPT 3726/4885KDM4E 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.